Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GlobalFoundries Inc. Ordinary Shares (GFS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

GlobalFoundries Inc. Ordinary SharesTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

GlobalFoundries Inc. Ordinary Shares vs Recursion Pharmaceuticals Inc — how do they compare? GlobalFoundries Inc. Ordinary Shares trades at $50.7 (market cap $26.80B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: GlobalFoundries Inc. Ordinary Shares is far larger — about 11.6× Recursion Pharmaceuticals Inc's market cap, and GlobalFoundries Inc. Ordinary Shares pays a 1% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GlobalFoundries Inc. Ordinary Shares for 0 Days and Recursion Pharmaceuticals Inc for 22 Days on average.

GFSRXRX
Market Cap
$26.80B$2.31B
Volume
2,967,33740,478,768
Sector
TechnologyHealth
52-Week High
$89.96$6.79
52-Week Low
$32.24$2.84
Typical Hold Time
0 Days22 Days
Enterprise Value
$26.09B$1.83B
Dividend Yield
1%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GlobalFoundries Inc. Ordinary Shares

No Aura AI signal available yet.

Recursion Pharmaceuticals Inc

RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.

The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GFS
51% Buy49% Sell
Avg holding period · 0 Days
RXRX
8% Buy92% Sell
Avg holding period · 22 Days

Top news

Latest headlines on both assets

About GlobalFoundries Inc. Ordinary Shares

GlobalFoundries is a semiconductor foundry that manufactures chips for other companies. Its technologies serve automotive, communications, industrial, and consumer markets.

Read more on GFS →

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX →